These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 23568995)

  • 41. Single-chain fragment variable passive immunotherapies for neurodegenerative diseases.
    Huang L; Su X; Federoff HJ
    Int J Mol Sci; 2013 Sep; 14(9):19109-27. PubMed ID: 24048248
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Protein aggregation and ER stress.
    Ogen-Shtern N; Ben David T; Lederkremer GZ
    Brain Res; 2016 Oct; 1648(Pt B):658-666. PubMed ID: 27037184
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of TDP-43 propagation in neurodegenerative diseases: integrating insights from clinical and experimental studies.
    Jo M; Lee S; Jeon YM; Kim S; Kwon Y; Kim HJ
    Exp Mol Med; 2020 Oct; 52(10):1652-1662. PubMed ID: 33051572
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Disease-associated amyloid and misfolded protein aggregates activate the inflammasome.
    Masters SL; O'Neill LA
    Trends Mol Med; 2011 May; 17(5):276-82. PubMed ID: 21376667
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Biomarkers of neurodegenerative disorders: how good are they?
    Rachakonda V; Pan TH; LE WD
    Cell Res; 2004 Oct; 14(5):347-58. PubMed ID: 15538967
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders.
    Neff F; Wei X; Nölker C; Bacher M; Du Y; Dodel R
    Autoimmun Rev; 2008 Jun; 7(6):501-7. PubMed ID: 18558370
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A universal method for detection of amyloidogenic misfolded proteins.
    Yam AY; Wang X; Gao CM; Connolly MD; Zuckermann RN; Bleu T; Hall J; Fedynyshyn JP; Allauzen S; Peretz D; Salisbury CM
    Biochemistry; 2011 May; 50(20):4322-9. PubMed ID: 21539296
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Linking Neuroinflammation and Neurodegeneration in Parkinson's Disease.
    Gelders G; Baekelandt V; Van der Perren A
    J Immunol Res; 2018; 2018():4784268. PubMed ID: 29850629
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nanoimaging for protein misfolding diseases.
    Lyubchenko YL; Kim BH; Krasnoslobodtsev AV; Yu J
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2010; 2(5):526-43. PubMed ID: 20665728
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Attempt to Untangle the Prion-Like Misfolding Mechanism for Neurodegenerative Diseases.
    Sarnataro D
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30304819
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Development of vaccination approaches for the treatment of neurological diseases.
    Federoff HJ
    J Comp Neurol; 2009 Jul; 515(1):4-14. PubMed ID: 19399901
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The alternative role of 14-3-3 zeta as a sweeper of misfolded proteins in disease conditions.
    Kaneko K; Hachiya NS
    Med Hypotheses; 2006; 67(1):169-71. PubMed ID: 16516399
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of extracellular vesicles in neurodegenerative diseases.
    Quek C; Hill AF
    Biochem Biophys Res Commun; 2017 Feb; 483(4):1178-1186. PubMed ID: 27659705
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Molecular chaperone dysfunction in neurodegenerative diseases and effects of curcumin.
    Maiti P; Manna J; Veleri S; Frautschy S
    Biomed Res Int; 2014; 2014():495091. PubMed ID: 25386560
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cdk5 at crossroads of protein oligomerization in neurodegenerative diseases: facts and hypotheses.
    Wilkaniec A; Czapski GA; Adamczyk A
    J Neurochem; 2016 Jan; 136(2):222-33. PubMed ID: 26376455
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Protein aggregation and neurodegenerative disease.
    Ross CA; Poirier MA
    Nat Med; 2004 Jul; 10 Suppl():S10-7. PubMed ID: 15272267
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Histochemical approaches to assess cell-to-cell transmission of misfolded proteins in neurodegenerative diseases.
    Natale G; Pompili E; Biagioni F; Paparelli S; Lenzi P; Fornai F
    Eur J Histochem; 2013 Mar; 57(1):e5. PubMed ID: 23549464
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Aptamer and its applications in neurodegenerative diseases.
    Qu J; Yu S; Zheng Y; Zheng Y; Yang H; Zhang J
    Cell Mol Life Sci; 2017 Feb; 74(4):683-695. PubMed ID: 27563707
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pathogenic role of ganglioside metabolism in neurodegenerative diseases.
    Ariga T
    J Neurosci Res; 2014 Oct; 92(10):1227-42. PubMed ID: 24903509
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting of Disordered Proteins by Small Molecules in Neurodegenerative Diseases.
    Longhena F; Spano P; Bellucci A
    Handb Exp Pharmacol; 2018; 245():85-110. PubMed ID: 28965171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.